DICE Therapeutics, Inc.
Clinical trials sponsored by DICE Therapeutics, Inc., explained in plain language.
Now part of
Eli Lilly and Company
LLY
NYSE
A biotech company developing oral small-molecule therapies for immunology, acquired by Eli Lilly.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.